A 54-WEEK, PHASE 2, MULTICENTER, MASKED, RANDOMIZED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INDOCYANINE GREEN-MEDIATED PHOTOTHROMBOSIS (i-MP) FOR THE TREATMENT OF PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Sponsor study identifier
interventional
280
1 country
1
Study Start
April 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
December 2008
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
To establish the safety and efficacy of indocyanine green-mediated photothrombosis (i-MP) for the treatment of patients with neovascular age-related macular degeneration.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2008
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 26, 2006
Actual (reported)May 29, 2006
Actual (reported)April 2007
Date type not reportedThis date has not been verified as actual or estimated.
December 2008
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Compare the groups in respect to proportion of eyes that lost less than 15 letters in ETDRS BCVA from baseline at week-54
Compare the groups in respect to proportion of eyes that did not present any loss in ETDRS BCVA (2 letters change) from baseline at week-54
Compare the groups in respect to mean change in ETDRS BCVA
Compare the groups in respect to neovascular complex activity (size and CNV leaking area)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Universidade Federal de Goias
Goiânia, Goias/Go, 00000, Brazil
Elizeu Ramos, M.S.
Opto Eletrônica S.A.
Avila Marcos, MD
Universidade Federal de Goias
First Submitted
May 26, 2006
First Posted
May 29, 2006
Study Start
April 2007
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
December 2008
Estimated (date passed)TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 27, 2007
Record last verified: 2007-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: